FUJIFILM Diosynth Biotechnologies Denmark ApSNovember 12, 2024

FDA 483 - FUJIFILM Diosynth Biotechnologies Denmark ApS - November 12, 2024

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore FUJIFILM Diosynth Biotechnologies Denmark ApS

Record Details

An FDA inspection of Fujifilm Diosynth Biotechnologies Denmark ApS in Hillerod revealed significant deficiencies across its drug substance manufacturing operations. The firm's Quality Unit demonstrated inadequate oversight, failing to ensure effective quality management, proper investigations, and adherence to procedures. Additionally, issues with electronic record integrity and incomplete production documentation were observed, indicating a broad lack of control over critical manufacturing processes.

Company: FUJIFILM Diosynth Biotechnologies Denmark ApS
Inspection Date: November 12, 2024
Product Type: Drugs
Office: Office of Inspections and Investigations
People: Richard Ledwidge (Biologist)
David D. Anderson
Richard Ledwidge
Leiyun W. Boone (Lead Biologist)
David Anderson

Open in Dashboard

ID · 2ec35f9a-5f16-4fee-ad57-6599d261113d